News

Saol Therapeutics Shares Exciting DCA Trial Results at Conference

Saol Therapeutics Shares Exciting DCA Trial Results at Conference

Saol Therapeutics Presents Key Findings on Sodium Dichloroacetate

Saol Therapeutics, a clinical-stage pharmaceutical company, has shared notable findings from its Phase III trial of Sodium Dichloroacetate (DCA) aimed at treating Pyruvate Dehydrogenase Complex Deficiency (PDCD). This presentation occurred during the Mitochondrial Medicine 2025 conference, showcasing the collaborative efforts of various stakeholders in the clinical trial process.

Insights from the Phase III Trial

During the presentation, CEO of Saol Therapeutics, Dave Penake, expressed gratitude towards patients, investigators, and trial sites for their invaluable contributions. The trial aimed to explore Sodium Dichloroacetate's effectiveness in treating PDCD, a rare and serious genetic disorder.

Adverse Reactions and Tolerability

One of the key outcomes indicated that DCA was well-tolerated by participants over an extended period, with a treatment duration exceeding three years. Gastrointestinal disorders were the most frequently reported adverse reactions, affecting 5.9% of the participants.

Assessing Efficacy Through Observer-Reported Outcomes

While the primary efficacy endpoint—the Observer Reported Outcome (ObsRO) survey—did not yield statistically significant results in the double-blind portion of the trial, there was a significant improvement in motor function during the open-label extension of the trial. This finding highlighted the long-term benefits of continued treatment.

Statistical Improvements Observed

Notably, DCA treatment led to a significant reduction in plasma lactate levels, coupled with a commendable improvement in survival rates compared to matched control groups. These statistics underscore the therapeutic potential of DCA for patients suffering from PDCD.

Future Directions for Saol Therapeutics

Looking ahead, Saol Therapeutics, along with Dr. Peter Stacpoole and other investigators, plans to submit the findings for publication, contributing to the growing body of knowledge regarding DCA's role in treating mitochondrial diseases.

DCA and Its Significance

DCA is an investigational product that could become pivotal in treating PDCD if approved. It works in conjunction with a genetic test designed to guide dosing, tailoring treatment to meet the unique needs of each patient. PDCD can lead to severe energy deficiencies causing serious complications, including developmental delays and life-threatening situations.

Fast Track and Collaborative Efforts

DCA has received important designations from the FDA, including Fast Track Designation and Orphan Drug Designation, ensuring it is eligible for Priority Review. Additionally, Saol Therapeutics, collaborating with Medosome Biotec, has applied for a Humanitarian Device Exemption (HDE) for the genetic test that will serve as a critical companion diagnostic for DCA treatment.

Expanded Access Program for PDCD Patients

For those patients with PDCD who did not participate in the clinical trial, Saol is actively conducting an expanded access program (EAP) to provide treatment options. This initiative aims to ensure eligible patients can access this potentially life-changing treatment, emphasizing Saol's commitment to patient care.

About Saol Therapeutics

Saol Therapeutics operates with a dedication to addressing central nervous system disorders and orphan diseases. With facilities in multiple locations, including Roswell, GA, Dublin, and Hamilton, Bermuda, the company is focused on improving therapeutic options for patients and their healthcare providers. They strive for innovation while ensuring the safety and efficacy of their products.

Saol Therapeutics Contact

For inquiries, Brian Nappi serves as the Senior Vice President of Strategy at Saol Therapeutics.

Frequently Asked Questions

What is Sodium Dichloroacetate used for?

Sodium Dichloroacetate is being investigated as a treatment for Pyruvate Dehydrogenase Complex Deficiency, a rare genetic disorder.

How long did the Phase III trial last?

The Phase III trial involved chronic administration of DCA for over three years, assessing its long-term efficacy and safety.

What were the main findings of the trial?

The trial found DCA to be well-tolerated, led to significant improvements in motor function, reduced plasma lactate levels, and improved survival rates.

What designations has DCA received from the FDA?

DCA has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for its potential therapeutic uses.

How can patients access DCA if they didn't participate in the trial?

Saol Therapeutics has initiated an expanded access program for eligible PDCD patients who were not part of the clinical trial, ensuring they can access potential treatment options.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 147

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 124

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 71

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 250

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 58

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 126

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 62

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading

Top 5 Most Recently Viewed Articles

Eimskip's Q3 2025 Financial Overview and Future Outlook

Updated Category News Views 238

Eimskip's Third Quarter Performance Analysis The results for the third quarter of 2025 have presented challenges for Eimskip, as operations did not meet expectations. Revenues showed significant shifts, revealing both obstacles and opportunities in the company's journey. Operational Insights During Q3, Eimskip experienced a slight increase in liner shipping volumes,...

Continue Reading
Market Trends and Insights: The Bullish Moves on Block

Updated Category News Views 88

Examining Recent Bullish Moves on Block Recently, financial institutions have been making significant bullish strides into Block, a company known for its innovative payment services. Analysis of the options trading history for Block (NASDAQ: SQ) indicates a noticeable interest, with 16 unusual trades captured, providing insights into market direction and trader sentiment....

Continue Reading
Exploring the Soaring Online Poker Market Growth Trends

Updated Category News Views 157

Online Poker Market: A Surge on the Horizon The Global Online Poker Market is currently undergoing a transformative expansion, predicted to rise from USD 7.98 billion in 2024 to an impressive USD 37.19 billion by 2030. This notable growth reflects a compound annual growth rate (CAGR) of 29.24%, driven by advancements in technology such as enhanced smartphone capabilities,...

Continue Reading
Elevate Your Gaming with Jackbit's New Crypto Welcome Offer

Updated Category News Views 182

Jackbit’s New Welcome Bonus for Crypto Players As online gaming evolves, Jackbit Crypto Casino is launching an exciting new welcome bonus tailored specifically for cryptocurrency enthusiasts. Starting next year, all new players joining the Jackbit platform will enjoy the same welcome bonuses that traditional fiat customers have been taking advantage of. This bold move...

Continue Reading
Eli Lilly's Mounjaro Drug Set to Revolutionize Weight Loss in Hong Kong

Updated Category News Views 214

Eli Lilly to Launch Weight Loss Drug Mounjaro in Hong Kong Eli Lilly & Co. (NYSE: LLY) is poised to launch its well-regarded weight-loss medication, Mounjaro, in Hong Kong shortly. This marks an exciting milestone, as it positions Mounjaro to be the first of its kind available in the broader region of China. The anticipated launch follows recent reports indicating that...

Continue Reading